A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Bexarotene (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms BEAT-AD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top